Cargando…

State of the Art in Exocrine Pancreatic Insufficiency

Exocrine pancreatic insufficiency (EPI) is defined as the maldigestion of foods due to inadequate pancreatic secretion, which can be caused by alterations in its stimulation, production, transport, or interaction with nutrients at duodenal level. The most frequent causes are chronic pancreatitis in...

Descripción completa

Detalles Bibliográficos
Autores principales: Diéguez-Castillo, Carmelo, Jiménez-Luna, Cristina, Prados, Jose, Martín-Ruiz, José Luis, Caba, Octavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599987/
https://www.ncbi.nlm.nih.gov/pubmed/33036352
http://dx.doi.org/10.3390/medicina56100523
_version_ 1783603017752248320
author Diéguez-Castillo, Carmelo
Jiménez-Luna, Cristina
Prados, Jose
Martín-Ruiz, José Luis
Caba, Octavio
author_facet Diéguez-Castillo, Carmelo
Jiménez-Luna, Cristina
Prados, Jose
Martín-Ruiz, José Luis
Caba, Octavio
author_sort Diéguez-Castillo, Carmelo
collection PubMed
description Exocrine pancreatic insufficiency (EPI) is defined as the maldigestion of foods due to inadequate pancreatic secretion, which can be caused by alterations in its stimulation, production, transport, or interaction with nutrients at duodenal level. The most frequent causes are chronic pancreatitis in adults and cystic fibrosis in children. The prevalence of EPI is high, varying according to its etiology, but it is considered to be underdiagnosed and undertreated. Its importance lies in the quality of life impairment that results from the malabsorption and malnutrition and in the increased morbidity and mortality, being associated with osteoporosis and cardiovascular events. The diagnosis is based on a set of symptoms, indicators of malnutrition, and an indirect non-invasive test in at-risk patients. The treatment of choice combines non-restrictive dietary measures with pancreatic enzyme replacement therapy to correct the associated symptoms and improve the nutritional status of patients. Non-responders require the adjustment of pancreatic enzyme therapy, the association of proton pump inhibitors, and/or the evaluation of alternative diagnoses such as bacterial overgrowth. This review offers an in-depth overview of EPI in order to support the proper management of this entity based on updated and integrated knowledge of its etiopathogenesis, prevalence, diagnosis, and treatment.
format Online
Article
Text
id pubmed-7599987
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75999872020-11-01 State of the Art in Exocrine Pancreatic Insufficiency Diéguez-Castillo, Carmelo Jiménez-Luna, Cristina Prados, Jose Martín-Ruiz, José Luis Caba, Octavio Medicina (Kaunas) Review Exocrine pancreatic insufficiency (EPI) is defined as the maldigestion of foods due to inadequate pancreatic secretion, which can be caused by alterations in its stimulation, production, transport, or interaction with nutrients at duodenal level. The most frequent causes are chronic pancreatitis in adults and cystic fibrosis in children. The prevalence of EPI is high, varying according to its etiology, but it is considered to be underdiagnosed and undertreated. Its importance lies in the quality of life impairment that results from the malabsorption and malnutrition and in the increased morbidity and mortality, being associated with osteoporosis and cardiovascular events. The diagnosis is based on a set of symptoms, indicators of malnutrition, and an indirect non-invasive test in at-risk patients. The treatment of choice combines non-restrictive dietary measures with pancreatic enzyme replacement therapy to correct the associated symptoms and improve the nutritional status of patients. Non-responders require the adjustment of pancreatic enzyme therapy, the association of proton pump inhibitors, and/or the evaluation of alternative diagnoses such as bacterial overgrowth. This review offers an in-depth overview of EPI in order to support the proper management of this entity based on updated and integrated knowledge of its etiopathogenesis, prevalence, diagnosis, and treatment. MDPI 2020-10-07 /pmc/articles/PMC7599987/ /pubmed/33036352 http://dx.doi.org/10.3390/medicina56100523 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Diéguez-Castillo, Carmelo
Jiménez-Luna, Cristina
Prados, Jose
Martín-Ruiz, José Luis
Caba, Octavio
State of the Art in Exocrine Pancreatic Insufficiency
title State of the Art in Exocrine Pancreatic Insufficiency
title_full State of the Art in Exocrine Pancreatic Insufficiency
title_fullStr State of the Art in Exocrine Pancreatic Insufficiency
title_full_unstemmed State of the Art in Exocrine Pancreatic Insufficiency
title_short State of the Art in Exocrine Pancreatic Insufficiency
title_sort state of the art in exocrine pancreatic insufficiency
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599987/
https://www.ncbi.nlm.nih.gov/pubmed/33036352
http://dx.doi.org/10.3390/medicina56100523
work_keys_str_mv AT dieguezcastillocarmelo stateoftheartinexocrinepancreaticinsufficiency
AT jimenezlunacristina stateoftheartinexocrinepancreaticinsufficiency
AT pradosjose stateoftheartinexocrinepancreaticinsufficiency
AT martinruizjoseluis stateoftheartinexocrinepancreaticinsufficiency
AT cabaoctavio stateoftheartinexocrinepancreaticinsufficiency